Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
August 14th, 2018
14K views
Here, we describe an in situ hybridization assay which enables sensitive and specific detection of sequences as short as 50 nucleotides with single-nucleotide resolution at the single-cell level. The assay, which can be performed manually or automatically, can enable visualization of splice variants, short sequences, and mutations within the tissue context.
Overview
This article presents an in situ hybridization assay that allows for the sensitive and specific detection of RNA sequences as short as 50 nucleotides at the single-cell level. The method is applicable in various fields, including neuroscience and oncology, facilitating the visualization of splice variants and mutations within tissue contexts.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Molecular Biology
Background
- In situ hybridization is a powerful technique for studying gene expression.
- Single-cell resolution allows for detailed analysis of cellular heterogeneity.
- Detection of splice variants and mutations is crucial for understanding disease mechanisms.
- The assay can be performed manually or automatically, enhancing its accessibility.
Purpose of Study
- To develop a method for detecting short RNA sequences with high sensitivity.
- To enable visualization of gene expression patterns in tissue samples.
- To facilitate research on cell type-specific expression in various biological contexts.
Methods Used
- Preparation of tissue samples using formalin fixation and paraffin embedding.
- Sectioning of tissue into thin slices for hybridization.
- Use of target retrieval reagents and hybridization probes.
- Amplification of signals using a series of reagents to enhance detection.
Main Results
- The assay successfully detected exon junctions and point mutations.
- High specificity and sensitivity were achieved in single-cell analyses.
- Visualization of splice variants was demonstrated in brain and tumor tissues.
- The method showed potential for broader applications in various research fields.
Conclusions
- This in situ hybridization assay is a valuable tool for molecular biology research.
- It provides insights into gene expression at the single-cell level.
- The technique can aid in understanding complex biological processes and diseases.
Frequently Asked Questions
What is the main advantage of this assay?
The main advantage is its ability to detect short RNA sequences and mutations with high sensitivity and specificity at the single-cell level.
In which fields can this method be applied?
This method can be applied in neuroscience, oncology, and other areas requiring detailed gene expression analysis.
How are tissue samples prepared for this assay?
Tissue samples are fixed in formalin, embedded in paraffin, and sectioned into thin slices for hybridization.
What types of sequences can be detected using this method?
The method can detect splice variants, short sequences, and point mutations.
Is the assay suitable for automated processing?
Yes, the assay can be performed manually or automatically, making it versatile for different laboratory settings.
Executive Industry Relevance
Accurate detection of RNA biomarkers in their native tissue context is critical for target validation and biomarker-driven drug development in oncology and neuroscience. This RNA in situ hybridization assay enables sensitive and specific visualization of splice variants, short sequences, and point mutations at single-cell resolution, supporting mechanistic de-risking and translational biomarker alignment. By preserving spatial information lost in grind-and-bind methods, it enhances predictive confidence in preclinical target selection and portfolio triage decisions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by visualizing exon junction-specific splice variants like EGFRvIII and METΔ14 in tissue context.
- Operational Value: Provides single-cell resolution data to clarify pathway activation and cellular heterogeneity in tumor microenvironments.
- Scientific Value: Supports functional target validation by distinguishing mutant from wild-type alleles at single-nucleotide resolution (e.g., EGFR L858R, KRAS G12A).
Screening & Assay Development
- Scientific Value: Detects RNA targets as short as 50 nucleotides, enabling CDR3 sequence profiling in immune repertoires for immuno-oncology target discovery.
- Operational Value: Compatible with automated staining platforms, supporting assay standardization and scalability across preclinical programs.
- Scientific Value: Generates quantitative, spatially resolved readouts that aid in assay optimization and reproducibility assessment.
Translational & Preclinical Research
- Scientific Value: Demonstrates disease relevance through detection of clinically actionable variants in FFPE glioblastoma and cell line models.
- Operational Value: Enables continuity from discovery to preclinical validation by maintaining morphological context during molecular analysis.
- Scientific Value: Facilitates biomarker alignment by linking genetic variants to cellular phenotypes in tissue sections.
Pipeline & Workflow Integration
The assay fits within the discovery continuum from target identification through lead optimization, particularly where spatial validation of genetic alterations informs target confidence and de-risking.
- Discovery Biology: Supports hypothesis testing of splice variant functionality and mutation impact in native tissue architecture.
- Screening: Enables preparation of validated biological systems for downstream compound screening via spatially resolved target confirmation.
- Analytics: Delivers quantitative, single-cell measurements of RNA variants that help compare experimental conditions and allelic ratios.
- Translational Research: Connects molecular findings to histopathological context, supporting biomarker-driven patient stratification models.
- Enterprise Reuse: Represents a reusable platform for longitudinal monitoring of target expression across models and therapeutic interventions.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity from bulk RNA methods.
- Operational Value: Ensures reproducibility through standardized protocols compatible with manual and automated workflows.
- Strategic Value: Improves go/no-go decisions by providing spatially resolved evidence of target engagement and variant prevalence.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on co-expression with phenotypic markers in tissue.
Implementation Considerations
- Requires expertise in immunohistochemistry, molecular pathology, and nucleic acid hybridization techniques.
- Dependent on access to hybridization ovens, slide processing systems, and automated stainers for high-throughput use.
- Necessitates cross-team standardization between histology, molecular biology, and bioinformatics for consistent probe design and data interpretation.
- Must account for tissue fixation variables (e.g., formalin penetration time) that may affect accessibility of short or structured RNA targets.
- Limited by target availability; efficacy depends on probe specificity and accessibility of epitopes in FFPE sections.
Biopharma FAQs
Why does single-nucleotide resolution matter for target validation?
The assay distinguishes point mutations like EGFR L858R from wild-type sequences at single-cell resolution, enabling precise assessment of allelic expression in heterogeneous tissues. This capability supports target validation by confirming mutant-specific signaling pathways without confounding from wild-type background. Such resolution is critical for de-risking targets in precision oncology programs where mutation status dictates therapeutic response.
How does exon junction detection support therapeutic hypothesis testing?
By targeting unique splice junctions (e.g., EGFRvIII, METΔ14), the assay validates the presence of pathogenic isoforms in their native tissue context, directly linking molecular alterations to disease phenotypes. This enables hypothesis-driven evaluation of splice variant function in tumorigenesis and resistance mechanisms. Spatial mapping of these variants informs target selection by revealing co-localization with proliferative or invasive cell populations.
What enables detection of short RNA sequences like CDR3 in situ?
The assay’s sensitivity allows detection of targets as short as 50 nucleotides, demonstrated by specific visualization of TCR CDR3-α and CDR3-β sequences in Jurkat cell pellets. This capability supports immune repertoire analysis in tumor microenvironments without requiring RNA extraction. Such short-sequence detection expands the range of actionable biomarkers accessible via spatial transcriptomics approaches.
Why are replication and controls essential for cross-functional reliability?
The protocol mandates positive and negative control probes (e.g., dapB) to confirm specificity and rule out background staining, ensuring data integrity across users and sites. Replicate washing and hybridization steps enhance reproducibility, which is vital for aligning histology, molecular biology, and bioinformatics teams. These controls support regulatory-grade assay qualification and technology transfer between discovery and translational groups.
What statistical outputs are needed before implementing this assay in screening cascades?
Implementation requires quantitative readouts such as signal-to-noise ratios, percentage of positive cells, and intensity distribution across replicates to establish assay robustness. These metrics enable comparison of splice variant or mutation prevalence under different experimental conditions, supporting data-driven go/no-go decisions. Thresholds for positivity should be defined using control samples and optimized via receiver operating characteristic (ROC) analysis when linking to functional endpoints.
Chapters in this video
0:04
Title
0:41
Tissue Preparation
1:30
Equipment and Reagent Preparation
3:24
Sample Deparaffinization, Dehydration, and Pre-treatment
5:26
Probe Hybridization, Signal Amplification, and Detection
7:18
Counterstaining, Slide Mounting, and Visualization
8:18
Results: Detection of Splice Variants, Short Sequences, and Point Mutation In Situ
10:00
Conclusion
